Home LiteratureArticle Details
PMID: 15122511 Published · ppublish English Comparative Study Journal Article Multicenter Study Research Support, Non-U.S. Gov't

CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies.

American journal of human genetics ·Vol. 74 ·No. 6 ·2004-06-00 ·Pages 1175-82

CHEK2 Breast Cancer Case-Control Consortium

Abstract

Previous studies of families with multiple cases of breast cancer have indicated that a frameshift alteration in the CHEK2 gene, 1100delC, is associated with an elevated frequency of breast cancer in such families, but the risk associated with the variant in other situations is uncertain. To evaluate the breast cancer risk associated with this variant, 10,860 breast cancer cases and 9,065 controls from 10 case-control studies in five countries were genotyped. CHEK2*1100delC was found in 201 cases (1.9%) and 64 controls (0.7%) (estimated odds ratio 2.34; 95% CI 1.72-3.20; P=.0000001). There was some evidence of a higher prevalence of CHEK2*1100delC among cases with a first-degree relative affected with breast cancer (odds ratio 1.44; 95% CI 0.93-2.23; P=.10) and of a trend for a higher breast cancer odds ratio at younger ages at diagnosis (P=.002). These results confirm that CHEK2*1100delC confers an increased risk of breast cancer and that this risk is apparent in women unselected for family history. The results are consistent with the hypothesis that CHEK2*1100delC multiplies the risks associated with susceptibility alleles in other genes to increase the risk of breast cancer.

MeSH Terms
Adult Aged Breast Neoplasms/diagnosis,epidemiology,genetics Case-Control Studies Checkpoint Kinase 2 Female Gene Expression Regulation, Neoplastic Genetic Predisposition to Disease Genetics, Population Genotype Humans Middle Aged Odds Ratio Protein Serine-Threonine Kinases/genetics Risk Factors Sequence Deletion
Chemicals
Checkpoint Kinase 2 CHEK2 protein, human Protein Serine-Threonine Kinases
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
CHEK2 Breast Cancer Case-Control Consortium
References (29)
29 references, click to expand
  1. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease.
    Lancet. 2001 Oct 27;358(9291):1389-99 PMID: 11705483
  2. A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes.
    Br J Cancer. 2002 Jan 7;86(1):76-83 PMID: 11857015
  3. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome.
    Science. 1999 Dec 24;286(5449):2528-31 PMID: 10617473
  4. Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53.
    Genes Dev. 2000 Feb 1;14(3):278-88 PMID: 10673500
  5. hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response.
    Nature. 2000 Mar 9;404(6774):201-4 PMID: 10724175
  6. Design and analysis issues in a population-based, case-control-family study of the genetic epidemiology of breast cancer and the Co-operative Family Registry for Breast Cancer Studies (CFRBCS).
    J Natl Cancer Inst Monogr. 1999;(26):95-100 PMID: 10854492
  7. Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro.
    Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10389-94 PMID: 10973490
  8. Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients.
    J Natl Cancer Inst. 2000 Sep 20;92(18):1529-31 PMID: 10995809
  9. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group.
    Br J Cancer. 2000 Nov;83(10):1301-8 PMID: 11044354
  10. Breastfeeding and breast cancer risk by age 50 among women in Germany.
    Cancer Causes Control. 2000 Sep;11(8):687-95 PMID: 11065005
  11. The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis.
    Nature. 2001 Apr 12;410(6830):842-7 PMID: 11298456
  12. Polymorphic catechol-O-methyltransferase gene and breast cancer risk.
    Cancer Epidemiol Biomarkers Prev. 2001 Jun;10(6):635-40 PMID: 11401913
  13. p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition.
    Cancer Res. 2001 Aug 1;61(15):5718-22 PMID: 11479205
  14. Spectrum of ATM gene mutations in a hospital-based series of unselected breast cancer patients.
    Cancer Res. 2001 Oct 15;61(20):7608-15 PMID: 11606401
  15. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations.
    Nat Genet. 2002 May;31(1):55-9 PMID: 11967536
  16. The progesterone receptor exon 4 Val660Leu G/T polymorphism and risk of breast cancer in Australian women.
    Cancer Epidemiol Biomarkers Prev. 2002 May;11(5):439-43 PMID: 12010857
  17. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer.
    Am J Hum Genet. 2002 Aug;71(2):432-8 PMID: 12094328
  18. Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility.
    Am J Hum Genet. 2003 Apr;72(4):1023-8 PMID: 12610780
  19. Frequency of CHEK2*1100delC in New York breast cancer cases and controls.
    BMC Med Genet. 2003 Jan 15;4:1 PMID: 12529183
  20. Common polymorphisms in checkpoint kinase 2 are not associated with breast cancer risk.
    Cancer Epidemiol Biomarkers Prev. 2003 Aug;12(8):809-12 PMID: 12917215
  21. Polygenic inheritance of breast cancer: Implications for design of association studies.
    Genet Epidemiol. 2003 Nov;25(3):190-202 PMID: 14557987
  22. The breast cancer low-penetrance allele 1100delC in the CHEK2 gene is not present in Spanish familial breast cancer population.
    Int J Cancer. 2004 Jan 1;108(1):54-6 PMID: 14618615
  23. Role of CHEK2*1100delC in unselected series of non-BRCA1/2 male breast cancers.
    Int J Cancer. 2004 Jan 20;108(3):477-8 PMID: 14648718
  24. CHEK2 variant I157T may be associated with increased breast cancer risk.
    Int J Cancer. 2004 Sep 10;111(4):543-7 PMID: 15239132
  25. Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: correlation with steroid receptors.
    Eur J Cancer. 1992;28(2-3):697-700 PMID: 1350457
  26. Identification of individuals by analysis of biallelic DNA markers, using PCR and solid-phase minisequencing.
    Am J Hum Genet. 1993 Jan;52(1):46-59 PMID: 8434605
  27. Replication checkpoint requires phosphorylation of the phosphatase Cdc25 by Cds1 or Chk1.
    Nature. 1998 Oct 1;395(6701):507-10 PMID: 9774107
  28. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase.
    Science. 1998 Dec 4;282(5395):1893-7 PMID: 9836640
  29. EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer.
    Br J Cancer. 1999 Jul;80 Suppl 1:95-103 PMID: 10466767
Article Info
Journal
American journal of human genetics
Abbr.
Am J Hum Genet
ISSN
0002-9297
Published
2004-06-00
Epub
2004-00-30
Pages
1175-82
Language
English
Region
United States
NLM ID
0370475
PMCID
PMC1182081
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]